机构：[1]Beijing Chest Hospital, Capital Medical University, Beijing/CN[2]Peking Union Medical College, Beijing/CN[3]The Fourth Hospital of Hebei Medical University, Shijiazhuang/CN河北医科大学第四医院[4]Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing/CN[5]Affiliated Hospital of Hebei University, Shijiazhuang/CN河北大学附属医院[6]Hebei Chest Hospital, Shijiazhuang/CN[7]The Affiliated Hospital of Inner Mongolia Medical University, Hohhot/CN[8]Affiliated People’s Hospital of Hebei Medical University, Shijiazhuang/CN[9]Tianjin Medical University General Hospital, Tianjin/CN[10]Harbin Medical University Cancer Hospital, Harbin/CN[11]Beijing Chao Yang Hospital of the Capital University of Medical Sciences, Beijing/CN北京朝阳医院[12]Inner Mongolia People’s Hospital, Hohhot/CN[13]Beijing Hospital, Beijing/CN[14]Tianjin People‘s Hospital, Tianjin/CN[15]Navy General Hospital of PLA., Beijing/CN[16]Xingtai People’s Hospital, Beijing/CN[17]Peking University Third Hospital, Beijing/CN
第一作者机构：[1]Beijing Chest Hospital, Capital Medical University, Beijing/CN
推荐引用方式(GB/T 7714)：
Li X.,Zhang L.,Jiang D.,et al.High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study[J].JOURNAL OF THORACIC ONCOLOGY.2018,13(12):S1049-S1049.doi:10.1016/j.jtho.2018.10.023.
APA：
Li, X.,Zhang, L.,Jiang, D.,Wang, Y.,Zang, A....&Zhang, S..(2018).High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study.JOURNAL OF THORACIC ONCOLOGY,13,(12)
MLA：
Li, X.,et al."High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study".JOURNAL OF THORACIC ONCOLOGY 13..12(2018):S1049-S1049
医学